Agilent Technologies Thought Leader Award Supports Dr. Ronald A. DePinho and Translational Research Program at MD Anderson

  Agilent Technologies Thought Leader Award Supports Dr. Ronald A. DePinho and
  Translational Research Program at MD Anderson Cancer Center

Business Wire

SANTA CLARA, Calif. -- February 27, 2013

Agilent Technologies Inc. (NYSE: A) today announced that Dr. Ronald A.
DePinho, a world-renowned oncologist and researcher, has received an Agilent
Thought Leader Award.

DePinho is president of the University of Texas MD Anderson Cancer Center. The
award will support his research into metabolic reprogramming in the earliest
stages of cancer.

DePinho and his team hope to discover and characterize alterations in
metabolic flux during tumor initiation and maintenance, and to identify
biomarkers for early detection of pancreatic cancer together with novel
therapeutic targets. Researchers on his team will work with scientists from
the university’s newly formed Institute of Applied Cancer Sciences.

The Agilent Thought Leader Award provides funds to support personnel as well
as a state-of-the-art Agilent 6550 iFunnel Q-TOF LC/MS system.

“I am extremely pleased to receive this award for metabolomics research, as
the survival rates for pancreatic cancer have not significantly improved over
the past 20 years,” DePinho said. “This technology will allow us to rapidly
identify new targets that drive the formation, progression and maintenance of
pancreatic cancer. Discoveries from this research will also lead to the
development of effective early detection biomarkers and novel therapeutic

“We are proud to support Dr. DePinho’s exciting translational research
program, which will make use of metabolomics and integrated biology workflows
and solutions in biomarker discovery,” said Patrick Kaltenbach, Agilent vice
president and general manager of the Liquid Phase Division. Kaltenbach is also
the executive sponsor of this award.

“The ability to investigate in a comprehensive, unbiased manner the metabolic
adaptations that occur during the development of pancreatic cancer will be
greatly enhanced by this [Agilent 6550 iFunnel Q-TOF LC/MS] instrument,” said
Dr. Giulio Draetta, director of the Institute for Applied Cancer Science. “The
insights gained from these studies will allow us to understand the changes
that occur during the evolution of pancreatic cancer. Armed with novel
biomarkers, earlier diagnosis and treatment will be possible, leading to
improved patient outcomes. Additional opportunities for novel therapeutic
intervention will also emerge from this work.”

The Agilent Thought Leader Program promotes fundamental scientific advances by
contributing financial support, products and expertise to the research of
influential thought leaders in the life sciences and chemical analysis fields.
Information about previous recipients is available at

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of
the world’s most respected centers focused on cancer patient care, research,
education and prevention. MD Anderson is one of only 41 comprehensive cancer
centers designated by the National Cancer Institute. For nine of the past 11
years, including 2012, MD Anderson has ranked No. 1 in cancer care in
“America’s Best Hospitals,” a survey published annually in U.S. News & World
Report. MD Anderson receives a cancer center support grant from the National
Cancer Institute of the National Institutes of Health.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company’s 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at

NOTE TO EDITORS: Further technology, corporate citizenship and executive news
is available at


Agilent Technologies Inc.
Susan Berg, +1 408-553-7093
Press spacebar to pause and continue. Press esc to stop.